Treatment of moderate to severe influenza

US11376265B2 · kind B2 · utility

Assignee

• ASPIAIR GMBH · DE

Inventors

• Karlheinz Nocker · Reiskirchen, DE
• Sebastian CANISIUS · Heskem-Mölln, DE
• Gerhard Scheuch · Kirchberg, DE

Key dates

• Filing date: Dec 22, 2016
• Grant date: Jul 5, 2022
• Expiry date: Jan 2, 2037

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P31/16
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides a compound, namely acetylsalicylic acid (ASA) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising ASA or a pharmaceutically acceptable salt thereof, for use in the treatment of a patient, e.g. a human being, suffering from a severe influenza virus infection and/or a symptom or condition associated therewith (namely, nasal congestion, sore throat, cough, fever, fatigue, headache and myalgias), wherein said use comprises the administration of a composition comprising ASA or a pharmaceutically acceptable salt thereof to the patient by inhalation.